Adjuvant Docetaxel for Node-Positive Breast Cancer
Hospital Clínico San Carlos · The Maria Sklodowska-Curie National Research Institute of Oncology · +18 more institutions
Indexed incrossrefpubmed
Abstract
Background
We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.
Methods
We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival.
Citation impact
951
total citations
- FWCI
- 39.37
- Percentile
- 100%
- References
- 29
Citations per year
Authors
32Topics & keywords
Topics
Keywords
- Medicine
- Docetaxel
- Adjuvant
- Breast cancer
- Oncology
- Internal medicine
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.